Despite advantages of bodily exercise, the extent of bodily exercise shouldn’t be fascinating in sufferers with sort 2 diabetes. The purpose of this research is the utilizing of integration of intervention primarily based on the speculation of safety motivation and implementation intention so as to enhance the extent of exercise in sufferers with diabetes.
This discipline trial research has been carried out on 125 sufferers with sort 2 diabetes. Samples have been randomly chosen, and they’re divided into two intervention and management teams. In the intervention group, coaching classes have been performed primarily based on the safety motivation principle and implementation intention.
Physical exercise ranges, VO2 max, and hemoglobin A1C have been measured earlier than and three months after the intervention within the two teams. Data have been analyzed through the use of SPSS 18, and impartial t-test, paired t-test, and equal nonparametric exams have been used for analyzing irregular information. The outcomes of this research confirmed that the extent of bodily exercise was increased within the intervention group (p = 0.02).
Also, the quantity of hemoglobin A1c within the intervention group has been decreased considerably three months later (p < 0.001). In this research, VO2 max and blood lipids weren’t considerably completely different within the two teams. However, there was increased VO2 max in contrast to earlier than the intervention within the intervention group.
The current research confirmed that combining motivational interventions and implementing intention intervention could be efficient in selling the bodily exercise of sufferers with sort 2 diabetes.
Association between sort 2 diabetes and osteoporosis danger: A consultant cohort research in Taiwan
Although earlier research have investigated the connection between fracture danger and sort 2 diabetes (T2D), cohort research that estimate composite osteoporosis danger are missing. This retrospective cohort research sought to decide the danger of osteoporosis in Taiwanese sufferers with T2D. Patients recognized with T2D between 2002 and 2015 recognized via the 2002 Taiwan Survey of Hypertension, Hyperglycemia, and Hyperlipidemia have been included.
A complete of 1690 males and 1641 girls aged ≥40 years linked to the National Health Insurance Research Database (NHIRD) have been adopted up to the tip of 2015 to determine the incidences of osteoporosis via ICD9-CM codes for osteoporosis or osteoporotic fractures or utilization of anti-osteoporotic brokers in accordance to Anatomical Therapeutic Chemical codes decided from NHIRD.
The particular person 12 months strategy and Kaplan-Meier evaluation have been then used to estimate the incidences and cumulative occasion charges, whereas the Cox proportional hazard mannequin was used to calculate adjusted hazard ratios (HR) for osteoporosis occasions.
A complete of 792 new osteoporosis occasions have been documented over a median follow-up period of 13.6 years. Participants with T2D had increased osteoporosis danger [adjusted HR: 1.37, 95% confidence interval (CI): 1.11-1.69] in contrast with these with out T2D. Subgroup analyses revealed that age had a slightly vital impact, indicating that T2D had a extra pronounced impact on osteoporosis danger in youthful inhabitants (<65 years outdated).
No distinction was discovered between sufferers stratified in accordance to intercourse. In conclusion, T2D was considerably related with elevated osteoporosis danger, particularly in youthful individuals.
Predictive Factors and Amputation Level for Reamputation in Patients With Diabetic Foot: A Retrospective Case-Control Study
The purpose of this research was to assess the speed and stage of reamputation in sufferers who had a earlier amputation from diabetic foot. We retrospectively analyzed sufferers who underwent amputation and reamputation due to diabetic foot in our clinic between 2011 and 2019. Fifty-nine have been evaluated because the healed group after the primary amputation and 55 have been evaluated because the reamputation group. Given 55 sufferers who wanted reamputation: there have been 13 finger or ray, 23 transmetatarsal or syme, 18 transtibial, and 1 transfemoral within the first operation. We discovered the reamputation price was 65.4% in distal amputations.
When serum parameters have been examined earlier than the primary amputation in every group, there was no statistically vital distinction in white blood cells, neutrophils, lymphocytes, platelets, sedimentation, C-reactive protein, complete protein, hematocrit, urea, creatinine, and HgA1c values.
There was, nevertheless, a big distinction between teams in albumin ranges. When comorbidities have been assessed for smoking, hypertension, period of diabetes, and quantity of debridements after the primary surgical procedure, a big distinction between teams was discovered.
When peripheral artery illness and continual renal failure have been examined, no vital distinction was noticed. In our research, it was noticed that the speed of reamputation was increased in distal stage amputations for diabetic foot sufferers. Accordingly, albumin values, smoking, hypertension, period of diabetes, quantity of debridements after surgical procedure, have been seen as danger components for reamputation sufferers.
National developments within the prevalence of glycemic management amongst sufferers with sort 2 diabetes receiving steady care in Thailand from 2011 to 2018
Diabetes is one of the most important international well being issues and reveals a continuously growing development. A collection of nationwide hospital-based cross-sectional surveys of medical outcomes was carried out yearly from 2011 to 2015 and 2018 amongst sufferers with sort 2 diabetes aged ≥ 20 years receiving medical look after no less than 12 months.
A two-stage stratified cluster that was proportional to the dimensions sampling method was used to choose a nationally and provincially consultant pattern of sufferers with sort 2 diabetes in Thailand. A complete of 186,010 sufferers with sort 2 diabetes have been enrolled within the research from 2011 to 2018. The prevalence of satisfactory glycemic management (hemoglobinA1c stage < 7.0%) amongst sufferers with sort 2 diabetes have been estimated to be 34.5% (95%CI 33.8-35.2%) in 2011, 33.0% (95%CI 32.4-33.6%) in 2012, 34.7% (95%CI 34.1-35.4%) in 2013, 35.5 (95%CI 34.9-36.1%) in 2014, 35.6 (95%CI 35.0-36.2%) in 2015, and 35.6% (95%CI 35.0-36.2%) in 2018, respectively (p for development < 0.001).
CXCL1 CRISPR Knock Out L3.6pl Cell Line |
|||
| T6221 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Ccl2 CRISPR Knock Out CT26 Cell Line |
|||
| T9611 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
SIRT CRISPR Knock Out Human HepG2 Cell Line - Clone T3-6 |
|||
| T6804 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
PRSS21 CRISPR Knock Out Human OVCAR8 Cell Line - Clone T2 C8 |
|||
| T6811 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
mAdrb2 CRISPR Knock Out B16 Cell Line (T1-10) |
|||
| T9775 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
TREM2 CRISPR Knock Out Human THP-1 Cell Line - Clone T1-9 |
|||
| T6810 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
PTPN6 CRISPR Knock Out Human THP-1 Cell Line - Clone T3-1 |
|||
| T6813 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
MSLN CRISPR Knock Out Human OVCAR3-A1 Cell Line - Clone T2 C4 |
|||
| T6820 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
NR2F6 CRISPR Knock Out Human Jurkat E6.1 Cell Line - Clone T3-10 |
|||
| T6822 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
NUAK2 CRISPR Knock Out 293T Cell Line - Clone T3 #41 |
|||
| T6801 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Aldh2 CRISPR Knock Out L929 Cell Line - Clone T3-20 |
|||
| T9692 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
hPIM1 CRISPR Knock Out SACC-83 Cell Line-T3-9 |
|||
| T9787 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Dcx CRISPR Knock Out C6 Cell Line (Rat) - Clone sg4-1 |
|||
| T9624 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
GLT1 CRISPR Knock Out Rat AST Cell Line - Clone T2-1 |
|||
| T9678 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
PTPN11 CRISPR Knock Out NIH/3T3 Cell Line - Clone T4-9 |
|||
| T6803 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
METTL3 CRISPR Knock Out Caki-1 Cell Line - Clone T2-16 |
|||
| T9623 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Nacc1 CRISPR Knock Out ID8 Cell Line (Mouse) - Clone T1-23 |
|||
| T9627 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
osbpl2 CRISPR Knock Out NIH/3T3 Cell Line - T1 Polyclonal Pool |
|||
| T9682 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
CARMIL1 CRISPR Knock Out Immortalized Human Gingival Fibroblast - hTERT Cell Line - T1-2 |
|||
| T6825 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Aifm1 CRISPR Knock Out Mouse L929 Cell Line - Clone T2-15-3 |
|||
| T9674 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
SEC61G CRISPR Knock Out HCC-LM3 Cell Line - Clone T2-17-5 |
|||
| T9746 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Human RRAD knockout cell line |
|||
| ABC-KH13200 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAD knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAD knockdown cell line |
|||
| ABC-KD13200 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAD knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Cell line gene knock-in and knock-out |
|||
| S301 | 101Bio | - | 15000 EUR |
Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T3-3 |
|||
| T9529 | ABM | 1x10^6 cells/1.0ml | 3950 EUR |
Araf CRISPR Knocked out RAW264.7 Stable cell Cell Line (Mouse) T1-19 |
|||
| T9511 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
RNH1 Stable Knockout K562 Cell Line |
|||
| T6157 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Stable Mouse Myeloid-derived Suppressor-like LAL Knock Out (HD1B) Cell Line |
|||
| T3187 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Human CD19 K562 Cell Line |
|||
| E24C00043 | EnoGene | each | 1225 EUR |
|
Description: Human |
|||
Human CD22 K562 Cell Line |
|||
| E24C00099 | EnoGene | each | 1225 EUR |
|
Description: Human |
|||
Human Siglec-15 K562 Cell Line |
|||
| E24C00225 | EnoGene | each | 1225 EUR |
|
Description: Human |
|||
BRCA1 CRISPR Stable Knockout Human Fibroblast Cell Line |
|||
| T6245 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
PTPRA CRISPR Knockout Immortalized Human Lung Fibroblast Cell Line |
|||
| T6827 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Human CD200R NFκB luci K562 Cell Line |
|||
| E24C00411 | EnoGene | each | 1225 EUR |
|
Description: Human |
|||
293AD Cell Line |
|||
| AD-100 | Cell Biolabs | 1 vial | 308 EUR |
|
Description: N/A |
|||
293AAV Cell Line |
|||
| AAV-100 | Cell Biolabs | 1 vial | 340 EUR |
|
Description: N/A |
|||
293LTV Cell Line |
|||
| LTV-100 | Cell Biolabs | 1 vial | 340 EUR |
|
Description: N/A |
|||
293RTV Cell Line |
|||
| RV-100 | Cell Biolabs | 1 vial | 340 EUR |
Human CRISP1 knockout cell line |
|||
| ABC-KH3569 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISP2 knockout cell line |
|||
| ABC-KH3570 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISP3 knockout cell line |
|||
| ABC-KH3571 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Acan CRISPR Knockout RCS Cell Line (Rat) |
|||
| T3000 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
293/GFP Cell Line |
|||
| AKR-200 | Cell Biolabs | 1 vial | 388 EUR |
|
Description: Fluorescence |
|||
T47D/GFP Cell Line |
|||
| AKR-208 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
A549/GFP Cell Line |
|||
| AKR-209 | Cell Biolabs | 1 vial | 388 EUR |
|
Description: Fluorescence |
|||
HeLa/GFP Cell Line |
|||
| AKR-213 | Cell Biolabs | 1 vial | 388 EUR |
|
Description: Fluorescence |
|||
293/Cas9 Cell Line |
|||
| AKR-5110 | Cell Biolabs | 1 vial | 460 EUR |
PTPN6 Stable Knocked Out THP-1 Cell Line |
|||
| T6216 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
HeLa/Cas9 Cell Line |
|||
| AKR-5111 | Cell Biolabs | 1 vial | 460 EUR |
NIH3T3/GFP Cell Line |
|||
| AKR-214 | Cell Biolabs | 1 vial | 388 EUR |
|
Description: Fluorescence |
|||
NIH3T3/Cas9 Cell Line |
|||
| AKR-5104 | Cell Biolabs | 1 vial | 460 EUR |
Human CRISPLD1 knockout cell line |
|||
| ABC-KH3572 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISPLD1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISPLD2 knockout cell line |
|||
| ABC-KH3573 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISPLD2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRISP1 knockdown cell line |
|||
| ABC-KD3569 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISP1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRISP2 knockdown cell line |
|||
| ABC-KD3570 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISP2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRISP3 knockdown cell line |
|||
| ABC-KD3571 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISP3 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
MCF-7/Luc Cell Line |
|||
| AKR-234 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
SKOV-3/Luc Cell Line |
|||
| AKR-232 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
OVCAR-5/RFP Cell Line |
|||
| AKR-254 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
| K2069901 | ABM | 3 x 1.0 ug | 406.8 EUR |
Human CRISPLD1 knockdown cell line |
|||
| ABC-KD3572 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISPLD1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRISPLD2 knockdown cell line |
|||
| ABC-KD3573 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRISPLD2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
K-562 [K562] Cell Line |
|||
| CL-0130 | Elabscience Biotech | 1×10⁶ cells/vial | 420 EUR |
|
Description: Homo sapiens, Human |
|||
TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
|||
| AST-7001 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 6 month |
|||
PLN Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
| iPS41 | ALSTEM | 1 Vial | 2268 EUR |
Human RRAS knockout cell line |
|||
| ABC-KH13205 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAS knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
LRP1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
| iPS31 | ALSTEM | 1 Vial | 2268 EUR |
AFF2 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
| iPS61 | ALSTEM | 1 Vial | 2268 EUR |
GFAT1 CRISPR Stable Knockout H1299 Cell Line |
|||
| T6199 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
ABCA7 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
| iPS21 | ALSTEM | 1 Vial | 2268 EUR |
KCNK3 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
| iPS51 | ALSTEM | 1 Vial | 2268 EUR |
LLGL1 Knock-out Human Induced Pluripotent Stem Cells (Episomal, HFF) |
|||
| iPS71 | ALSTEM | 1 Vial | 2268 EUR |
Human RRAGA knockout cell line |
|||
| ABC-KH13201 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGA knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGB knockout cell line |
|||
| ABC-KH13202 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGB knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGC knockout cell line |
|||
| ABC-KH13203 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGC knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAGD knockout cell line |
|||
| ABC-KH13204 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGD knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human RRAS2 knockout cell line |
|||
| ABC-KH13206 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAS2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
EDC4 CRISPR Stable Knockout HEK293T Cell Line |
|||
| T6241 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
DJ-1 CRISPR Stable Knockout HeLa Cell Line |
|||
| T6181 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
RRAD 3'UTR GFP Stable Cell Line |
|||
| TU072380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU269725 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU168183 | ABM | 1.0 ml | Ask for price |
PDPN CRISPR Stable Knockout COS-7 Cell Line |
|||
| T6039 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
PD-L1 CRISPR Stable Knockout MC38 Cell Line |
|||
| T6149 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
PD-L1 CRISPR Stable Knockout CT26 Cell Line |
|||
| T6237 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Cas9 Expressing K562 Cell Line |
|||
| T3258 | ABM | 1x10^6 cells / 1.0 ml | 795 EUR |
TARGATT? Knock-in iPSC Generation (Master Cell Line) |
|||
| AST-1100 | Applied StemCell | 1 vial of 1X10^6 cells | Ask for price |
|
Description: 6 month |
|||
LIMD1-/- CRISPR Stable Knockout HeLa Cell Line |
|||
| T6357 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Firefly Luciferase K562 Cell Line |
|||
| 78621 | BPS Bioscience | 2 vials | 1900 EUR |
|
Description: Recombinant K562 cells constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter. |
|||
K562-CDH-GFP Cell line |
|||
| T9552 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Human RRAS knockdown cell line |
|||
| ABC-KD13205 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAS knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
SLC35A1 CRISPR Stable Knockout CHO-S Cell Line |
|||
| T6040 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
CXCL1 & CXCL8 CRISPR Double Knockout L3.6pl Cell Line |
|||
| T6047 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K2069902 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K2069903 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K2069904 | ABM | 1.0 ug DNA | 184.8 EUR |
Human RRAGA knockdown cell line |
|||
| ABC-KD13201 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGA knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAGB knockdown cell line |
|||
| ABC-KD13202 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGB knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAGC knockdown cell line |
|||
| ABC-KD13203 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGC knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAGD knockdown cell line |
|||
| ABC-KD13204 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAGD knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human RRAS2 knockdown cell line |
|||
| ABC-KD13206 | AcceGen | 1 vial | Ask for price |
|
Description: Human RRAS2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU118183 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU219725 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
| TU022380 | ABM | 1.0 ml | 1672.8 EUR |
AXL CRISPR Stable Knockout HT1080 (1-IV) Cell Line |
|||
| T6232 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
AXL CRISPR Stable Knockout HT1080 (3-II) Cell Line |
|||
| T6233 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
|||
| RV-101 | Cell Biolabs | 1 vial | 648 EUR |
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
|||
| RV-103 | Cell Biolabs | 1 vial | 648 EUR |
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
|||
| RV-102 | Cell Biolabs | 1 vial | 648 EUR |
Total Protein - Murine Embryonic Stem Cell Line D3 |
|||
| CBA-305 | Cell Biolabs | 500 ?g | 414 EUR |
|
Description:
|
|||
TARGATT? Knock-in CHO Generation Kit (Master Cell Line) |
|||
| AST-1200 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line) |
|||
| AST-1300 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
RPS15A Stably Expressing K562 Cell Line |
|||
| T6433 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Lyophilized microvesicles from K562 cell line |
|||
| HBM-mvK562-50 | HansaBioMed | > 1x109 particles/ml | 211.68 EUR |
Mouse NACC1 CRISPR Stable Knockout ID8 Cell Line - Clone T1-23 |
|||
| T6826 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Human K562 Cell Lysate |
|||
| IHUK562TL100UG | Innovative research | each | 245 EUR |
|
Description: Human K562 Cell Lysate |
|||
Human K562 Cell Lysate |
|||
| MBS8413836-01mg | MyBiosource | 0.1mg | 385 EUR |
Human K562 Cell Lysate |
|||
| MBS8413836-5x01mg | MyBiosource | 5x0.1mg | 1540 EUR |
Human CRIM1 knockout cell line |
|||
| ABC-KH3563 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIM1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRIP1 knockout cell line |
|||
| ABC-KH3564 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRIP2 knockout cell line |
|||
| ABC-KH3565 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRIP3 knockout cell line |
|||
| ABC-KH3566 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRIPT knockout cell line |
|||
| ABC-KH3568 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIPT knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CRIPAK knockout cell line |
|||
| ABC-KH3567 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIPAK knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
HLA-DQ8 Expressing Stable K562 Cell Line |
|||
| T3209 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
miR-34a Stably Expressing K562 Cell Line |
|||
| T6450 | ABM | 1x10^6 cells / 1.0 ml | 3950 EUR |
Lyophilized exosomes from K562 MG cell line |
|||
| HBM-K562-100/2 | HansaBioMed | 2x100µg vial | 249.48 EUR |
Lyophilized exosomes from K562 MG cell line |
|||
| HBM-K562-100/5 | HansaBioMed | 5x100µg vial | 487.62 EUR |
Lyophilized exosomes from K562 MG cell line |
|||
| HBM-K562-30/2 | HansaBioMed | 2x30µg vial | 189 EUR |
Lyophilized exosomes from K562 MG cell line |
|||
| HBM-K562-30/5 | HansaBioMed | 5x30µg vial | 400.68 EUR |
hCETP shRNA (Target C) Knock Down THP-1 Cell Line-Polyclone |
|||
| T9789 | ABM | 1x10^6 cells / 1.0 ml | Ask for price |
Cynomolgus / Rhesus Macaque CD19 K562 Cell Line |
|||
| E24C00044 | EnoGene | each | 1225 EUR |
|
Description: Cynomolgus / Rhesus Macaque |
|||
Cynomolgus / Rhesus Macaque CD22 K562 Cell Line |
|||
| E24C00100 | EnoGene | each | 1225 EUR |
|
Description: Cynomolgus / Rhesus Macaque |
|||
Human CRIM1 knockdown cell line |
|||
| ABC-KD3563 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIM1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRIP1 knockdown cell line |
|||
| ABC-KD3564 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIP1 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRIP2 knockdown cell line |
|||
| ABC-KD3565 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIP2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRIP3 knockdown cell line |
|||
| ABC-KD3566 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIP3 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRIPT knockdown cell line |
|||
| ABC-KD3568 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIPT knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human CRIPAK knockdown cell line |
|||
| ABC-KD3567 | AcceGen | 1 vial | Ask for price |
|
Description: Human CRIPAK knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2069905 | ABM | 3 x 1.0 ug | 451.2 EUR |
Human AR knockout cell line |
|||
| ABC-KH0856 | AcceGen | 1 vial | Ask for price |
|
Description: Human AR knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human F2 knockout cell line |
|||
| ABC-KH5009 | AcceGen | 1 vial | Ask for price |
|
Description: Human F2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human F3 knockout cell line |
|||
| ABC-KH5014 | AcceGen | 1 vial | Ask for price |
|
Description: Human F3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human F5 knockout cell line |
|||
| ABC-KH5015 | AcceGen | 1 vial | Ask for price |
|
Description: Human F5 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human F7 knockout cell line |
|||
| ABC-KH5016 | AcceGen | 1 vial | Ask for price |
|
Description: Human F7 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human F8 knockout cell line |
|||
| ABC-KH5017 | AcceGen | 1 vial | Ask for price |
|
Description: Human F8 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human F9 knockout cell line |
|||
| ABC-KH5021 | AcceGen | 1 vial | Ask for price |
|
Description: Human F9 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human GC knockout cell line |
|||
| ABC-KH5948 | AcceGen | 1 vial | Ask for price |
|
Description: Human GC knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human GK knockout cell line |
|||
| ABC-KH6087 | AcceGen | 1 vial | Ask for price |
|
Description: Human GK knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human HP knockout cell line |
|||
| ABC-KH6972 | AcceGen | 1 vial | Ask for price |
|
Description: Human HP knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human HR knockout cell line |
|||
| ABC-KH6992 | AcceGen | 1 vial | Ask for price |
|
Description: Human HR knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human C2 knockout cell line |
|||
| ABC-KH1951 | AcceGen | 1 vial | Ask for price |
|
Description: Human C2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human C3 knockout cell line |
|||
| ABC-KH2027 | AcceGen | 1 vial | Ask for price |
|
Description: Human C3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human C5 knockout cell line |
|||
| ABC-KH2074 | AcceGen | 1 vial | Ask for price |
|
Description: Human C5 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human C6 knockout cell line |
|||
| ABC-KH2100 | AcceGen | 1 vial | Ask for price |
|
Description: Human C6 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human C7 knockout cell line |
|||
| ABC-KH2130 | AcceGen | 1 vial | Ask for price |
|
Description: Human C7 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human C9 knockout cell line |
|||
| ABC-KH2174 | AcceGen | 1 vial | Ask for price |
|
Description: Human C9 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CP knockout cell line |
|||
| ABC-KH3480 | AcceGen | 1 vial | Ask for price |
|
Description: Human CP knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CS knockout cell line |
|||
| ABC-KH3611 | AcceGen | 1 vial | Ask for price |
|
Description: Human CS knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human PC knockout cell line |
|||
| ABC-KH11173 | AcceGen | 1 vial | Ask for price |
|
Description: Human PC knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human TF knockout cell line |
|||
| ABC-KH15318 | AcceGen | 1 vial | Ask for price |
|
Description: Human TF knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human TG knockout cell line |
|||
| ABC-KH15342 | AcceGen | 1 vial | Ask for price |
|
Description: Human TG knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human TH knockout cell line |
|||
| ABC-KH15368 | AcceGen | 1 vial | Ask for price |
|
Description: Human TH knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human XG knockout cell line |
|||
| ABC-KH17067 | AcceGen | 1 vial | Ask for price |
|
Description: Human XG knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human XK knockout cell line |
|||
| ABC-KH17074 | AcceGen | 1 vial | Ask for price |
|
Description: Human XK knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human KL knockout cell line |
|||
| ABC-KH7942 | AcceGen | 1 vial | Ask for price |
|
Description: Human KL knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human KY knockout cell line |
|||
| ABC-KH8250 | AcceGen | 1 vial | Ask for price |
|
Description: Human KY knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human T knockout cell line |
|||
| ABC-KH15011 | AcceGen | 1 vial | Ask for price |
|
Description: Human T knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human MB knockout cell line |
|||
| ABC-KH9065 | AcceGen | 1 vial | Ask for price |
|
Description: Human MB knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human SI knockout cell line |
|||
| ABC-KH13776 | AcceGen | 1 vial | Ask for price |
|
Description: Human SI knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LIN37 knockout cell line |
|||
| ABC-KH8476 | AcceGen | 1 vial | Ask for price |
|
Description: Human LIN37 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human CEL knockout cell line |
|||
| ABC-KH2905 | AcceGen | 1 vial | Ask for price |
|
Description: Human CEL knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LINS knockout cell line |
|||
| ABC-KH8486 | AcceGen | 1 vial | Ask for price |
|
Description: Human LINS knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LIN7A knockout cell line |
|||
| ABC-KH8477 | AcceGen | 1 vial | Ask for price |
|
Description: Human LIN7A knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LIN7B knockout cell line |
|||
| ABC-KH8478 | AcceGen | 1 vial | Ask for price |
|
Description: Human LIN7B knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LIN7C knockout cell line |
|||
| ABC-KH8479 | AcceGen | 1 vial | Ask for price |
|
Description: Human LIN7C knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LIN28A knockout cell line |
|||
| ABC-KH8474 | AcceGen | 1 vial | Ask for price |
|
Description: Human LIN28A knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human LIN28B knockout cell line |
|||
| ABC-KH8475 | AcceGen | 1 vial | Ask for price |
|
Description: Human LIN28B knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZFR knockout cell line |
|||
| ABC-KH17303 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZFR knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZFX knockout cell line |
|||
| ABC-KH17305 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZFX knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZFY knockout cell line |
|||
| ABC-KH17306 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZFY knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZP1 knockout cell line |
|||
| ABC-KH17866 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZP1 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZP2 knockout cell line |
|||
| ABC-KH17867 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZP2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZP3 knockout cell line |
|||
| ABC-KH17868 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZP3 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZP4 knockout cell line |
|||
| ABC-KH17869 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZP4 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ZYX knockout cell line |
|||
| ABC-KH17911 | AcceGen | 1 vial | Ask for price |
|
Description: Human ZYX knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human A2M knockout cell line |
|||
| ABC-KH0003 | AcceGen | 1 vial | Ask for price |
|
Description: Human A2M knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ABO knockout cell line |
|||
| ABC-KH0100 | AcceGen | 1 vial | Ask for price |
|
Description: Human ABO knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ABR knockout cell line |
|||
| ABC-KH0101 | AcceGen | 1 vial | Ask for price |
|
Description: Human ABR knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ACD knockout cell line |
|||
| ABC-KH0140 | AcceGen | 1 vial | Ask for price |
|
Description: Human ACD knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ACE knockout cell line |
|||
| ABC-KH0141 | AcceGen | 1 vial | Ask for price |
|
Description: Human ACE knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ACR knockout cell line |
|||
| ABC-KH0176 | AcceGen | 1 vial | Ask for price |
|
Description: Human ACR knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ADA knockout cell line |
|||
| ABC-KH0234 | AcceGen | 1 vial | Ask for price |
|
Description: Human ADA knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ADC knockout cell line |
|||
| ABC-KH0290 | AcceGen | 1 vial | Ask for price |
|
Description: Human ADC knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ADK knockout cell line |
|||
| ABC-KH0326 | AcceGen | 1 vial | Ask for price |
|
Description: Human ADK knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ADM knockout cell line |
|||
| ABC-KH0327 | AcceGen | 1 vial | Ask for price |
|
Description: Human ADM knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human ADO knockout cell line |
|||
| ABC-KH0332 | AcceGen | 1 vial | Ask for price |
|
Description: Human ADO knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human AEN knockout cell line |
|||
| ABC-KH0359 | AcceGen | 1 vial | Ask for price |
|
Description: Human AEN knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human AES knockout cell line |
|||
| ABC-KH0360 | AcceGen | 1 vial | Ask for price |
|
Description: Human AES knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human AFM knockout cell line |
|||
| ABC-KH0368 | AcceGen | 1 vial | Ask for price |
|
Description: Human AFM knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Independent components associated to poor glycemic management (hemoglobinA1c ≥ 7%) have been being feminine, youthful aged, dwelling within the northeastern area, obtained care type hospitals decrease than regional stage, underneath common well being protection scheme, higher period of diabetes, increased physique mass index stage and absence of hypertension comorbidity.